• Revenue growth outlook: Management expects to maintain a 30%+ CAGR over the next 2 to 3 years, with a potential upside of 3% to 5% driven by broad-based product traction.
• Debt reduction trajectory: Pre-IPO and IPO proceeds lowered debt to an effective ₹900 crore carrying a subsidized 5.5% interest rate, with regular annual repayments of around ₹100 crore expected to bring debt down to the ₹800–900 crore range in FY27.
• ROCE target: After reaching 16% in Q1, return on capital employed is projected to stabilize between 20% and 22% over the next 2 to 3 years despite ongoing capital expenditure plans.
• Whey protein expansion: The upcoming whey protein facility is scheduled to become operational in 15 to 18 months and is anticipated to add ₹2,000 to ₹2,500 crore to top-line revenue over the next 2 to 3 years.
• Operating margin profile: Margins are guided to stay near 15% for FY27, with room for upside as high-margin product lines such as Greek yogurt, high-protein items, and ice creams continue to expand.